For example, in the therapeutic aspects, aptamers modified with GC sequences were affixed with Adriamycin to specifically target multiple myeloma cells and inhibit tumor growth in multiple myeloma [28]; in addition, aptamer-engineered NK cells generated by anchoring the aptamer to the surface of NK cells can specifically bind CD30-expressing lymphoma cells without genetic alteration [29]. This evidence concerns the gene TNFRSF8 and plasma cell myeloma.